KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Free Cash Flow (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Free Cash Flow for 15 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 56.02% to $19.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.0 million, a 73.14% decrease, with the full-year FY2025 number at $46.0 million, down 73.14% from a year prior.
  • Free Cash Flow was $19.4 million for Q4 2025 at Supernus Pharmaceuticals, up from -$61.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $71.1 million in Q2 2022 to a low of -$61.8 million in Q3 2025.
  • A 5-year average of $28.6 million and a median of $36.0 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 1201.57% in 2023, then plummeted 215.89% in 2025.
  • Supernus Pharmaceuticals' Free Cash Flow stood at $48.8 million in 2021, then tumbled by 43.45% to $27.6 million in 2022, then skyrocketed by 63.18% to $45.0 million in 2023, then dropped by 1.78% to $44.2 million in 2024, then plummeted by 56.02% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Free Cash Flow are $19.4 million (Q4 2025), -$61.8 million (Q3 2025), and $58.1 million (Q2 2025).